| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 309.1 | 257.5 | 247.1 |
| Other income | 10.2 | 12.8 | 13.4 |
| Total income | 319.2 | 270.3 | 260.4 |
| Profit before exceptional items & tax | 96.1 | 77.1 | 83.4 |
| Profit before tax | 95.5 | 78.3 | 85.7 |
| Net profit | 69.6 | 57.7 | 63.1 |
| Operating margin | 29.9% | 29.0% | 32.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +10.30% |
|---|---|
| Net profit, quarter on quarter | +20.60% |
| Revenue, year on year | +25.10% |
| Operating profit, year on year | +22.70% |
| Operating profit, quarter on quarter | +33.60% |
BSE results filing, NSE: CONCORDBIO. Figures extracted from the filing.
Concord Biotech Ltd: key numbers
- Share price
- ₹1,268.50
- Market cap
- ₹13,271 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 47.0×Sector 46.1×
- Promoter holding
- 44.09%+0.01% QoQ
- FII holding
- 7.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Earnings Call Transcript: Key Takeaways
Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.
- Call
- Guides 18% growth
Concord Biotech Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.
Concord Biotech Bonus Issue
Concord Biotech fixed 4 November 2026 as the record date for a 1:1 bonus issue, with deemed allotment on 5 November 2026. The bonus is subject to statutory and regulatory approvals.
Concord Biotech Bonus Issue
Concord Biotech's postal ballot approved a bonus issue and an authorised capital increase. No cash is paid and no ratio is stated.
Concord Biotech Board Meeting Date
Concord Biotech has scheduled its Q2 FY27 board meeting for 27 Oct 2026 to approve standalone and consolidated results. Trading window remains closed until 48 hours post result declaration.
Concord Biotech Other Announcement
Concord Biotech Ltd has filed its quarterly shareholding pattern under Regulation 31 for the period ended September 30, 2026.